DeepCure Launches Clinical Trial Combining Robotic Laparoscopic RDN and AI Guide
DeepCure is launching the world's first clinical trial in Korea to validate an artificial intelligence (AI) guide for extravascular renal denervation (Extravascular RDN) using a robotic laparoscopic approach, targeting patients with resistant hypertension.
According to DeepCure on June 25, this clinical trial is part of a strategy to achieve a unique technological differentiation in the global medical device market by applying DeepCure's HyperQure™ RDN system to existing advanced robotic surgery infrastructure and utilizing the HyperQure Navigator, an AI-powered surgical guide program developed by DeepCure.
This investigator-initiated feasibility clinical trial is being conducted based on approval from the Ministry of Food and Drug Safety and a research contract with Seoul National University Hospital. The trial is led by Professor Changwook Jung and Professor Janghee Han's team.
In particular, this clinical trial will utilize the HyperQure Navigator, an AI-based medical imaging software that recently received Class I digital medical device manufacturing approval from the Ministry of Food and Drug Safety. The HyperQure Navigator analyzes patients' renal computed tomography angiography (CTA) images using AI algorithms to quantify renal vascular information and provide it to medical professionals. It was developed to enhance the consistency and safety of extravascular renal denervation procedures.
Hot Picks Today
Retail Investors Regain Hope: "Leverage Unwinding Nears End, KOSPI 12,500 Target Intact," Says J.P. Morgan
- "$300 Gone in One Date"...U.S. Gen Z Ditches Restaurants for Parks
- "There Are Rules About Fines!" Even Presidential Rebuke as Turkey's Anti-Smoking Crackdown Imposes 21.8 Billion Won in Penalties
- After Much Deliberation, We End Up Saying "Just an Iced Americano"... What Happens When There Are Too Many Choices
- Zara 'Death Pants' Too Stylish to Give Up: "I Almost Died Just 30 Minutes After Putting Them On"
A DeepCure representative stated, "This clinical trial and the regulatory approval of the AI navigation system will serve as a milestone proving that DeepCure is a medtech company with complete capabilities in both hardware (robotic laparoscopic RDN equipment) and software (AI surgical guide). By leveraging differentiated value through advanced robotic extravascular renal denervation and medical AI, we will accelerate our entry into the global market and maximize the company's value."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
